Literature DB >> 17804499

Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation.

Haitao Guo1, Dong Jiang, Tianlun Zhou, Andrea Cuconati, Timothy M Block, Ju-Tao Guo.   

Abstract

Covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is formed by conversion of capsid-associated relaxed circular DNA (rcDNA) via unknown mechanisms and exists in the nucleus of the infected hepatocyte as a minichromosome that serves as the transcription template for viral RNAs. To study the molecular pathway of cccDNA formation and its regulation by viral and cellular factors, we have established a cell line that supports the replication of an envelope protein-deficient HBV genome in a tetracycline-inducible manner. Following induction of HBV replication, the cells accumulate higher levels of cccDNA as well as larger amounts of deproteinized rcDNA (DP-rcDNA) than cells that replicate wild-type HBV genomes. These results indicate that HBV envelope proteins negatively regulate cccDNA formation, and conversion of DP-rcDNA into cccDNA is a rate-limiting step of cccDNA formation in HepG2 cells. Detailed analyses reveal the following: (i) DP-rcDNA exists in both cytoplasm and nucleus; (ii) while nuclear DP-rcDNA is sensitive to DNase I digestion, a small fraction of cytoplasmic DP-rcDNA is DNase I resistant; (iii) both DNase I-sensitive and -resistant cytoplasmic DP-rcDNAs cosediment with capsids and can be immunoprecipitated with HBV core antibody; and (iv) a primer extension assay maps the 5' end of the minus strand of DP-rcDNA at the authentic end of virion rcDNA. Hence, our results favor a hypothesis that the removal of viral polymerase protein covalently linked to the 5' end of the minus-strand DNA occurs inside the capsid in the cytoplasm and most possibly via a reaction that cleaves the phosphodiester bond between the tyrosine of the polymerase and the 5' phosphoryl group of minus-strand DNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804499      PMCID: PMC2169032          DOI: 10.1128/JVI.01123-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Mutations that increase in situ priming also decrease circularization for duck hepatitis B virus.

Authors:  D D Loeb; R Tian
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Does a cdc2 kinase-like recognition motif on the core protein of hepadnaviruses regulate assembly and disintegration of capsids?

Authors:  M I Barrasa; J T Guo; J Saputelli; W S Mason; C Seeger
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors.

Authors:  S Ren; M Nassal
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice.

Authors:  A K Raney; C M Eggers; E F Kline; L G Guidotti; M Pontoglio; M Yaniv; A McLachlan
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

Authors:  Y Zhu; T Yamamoto; J Cullen; J Saputelli; C E Aldrich; D S Miller; S Litwin; P A Furman; A R Jilbert; W S Mason
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

Authors:  Ching-Lung Lai; Mohamed Rosmawati; Judy Lao; Hans Van Vlierberghe; Frank H Anderson; Neal Thomas; Deborah Dehertogh
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

7.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  Y F Liaw; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; R N Chien; J Dent; L Roman; S Edmundson; C L Lai
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

8.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Patrick Marcellin; Ting-Tsung Chang; Seng Gee Lim; Myron J Tong; William Sievert; Mitchell L Shiffman; Lennox Jeffers; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

9.  Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver.

Authors:  R H Miller; W S Robinson
Journal:  Virology       Date:  1984-09       Impact factor: 3.616

10.  Conditional replication of duck hepatitis B virus in hepatoma cells.

Authors:  Ju-Tao Guo; Melissa Pryce; Xingtai Wang; M Inmaculada Barrasa; Jianming Hu; Christoph Seeger
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  159 in total

1.  Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.

Authors:  Dawei Cai; Courtney Mills; Wenquan Yu; Ran Yan; Carol E Aldrich; Jeffry R Saputelli; William S Mason; Xiaodong Xu; Ju-Tao Guo; Timothy M Block; Andrea Cuconati; Haitao Guo
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Identification of an Intermediate in Hepatitis B Virus Covalently Closed Circular (CCC) DNA Formation and Sensitive and Selective CCC DNA Detection.

Authors:  Jun Luo; Xiuji Cui; Lu Gao; Jianming Hu
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

3.  Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H.

Authors:  Elena Lomonosova; Jil Daw; Aswin K Garimallaprabhakaran; Nana B Agyemang; Yashkumar Ashani; Ryan P Murelli; John E Tavis
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

Review 4.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

5.  Differential assembly of Hepatitis B Virus core protein on single- and double-stranded nucleic acid suggest the dsDNA-filled core is spring-loaded.

Authors:  Mary S Dhason; Joseph C-Y Wang; Michael F Hagan; Adam Zlotnick
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

6.  Maturation-associated destabilization of hepatitis B virus nucleocapsid.

Authors:  Xiuji Cui; Laurie Ludgate; Xiaojun Ning; Jianming Hu
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

7.  Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.

Authors:  Nagraj Mani; Andrew G Cole; Janet R Phelps; Andrzej Ardzinski; Kyle D Cobarrubias; Andrea Cuconati; Bruce D Dorsey; Ellen Evangelista; Kristi Fan; Fang Guo; Haitao Guo; Ju-Tao Guo; Troy O Harasym; Salam Kadhim; Steven G Kultgen; Amy C H Lee; Alice H L Li; Quanxin Long; Sara A Majeski; Richeng Mao; Kevin D McClintock; Stephen P Reid; Rene Rijnbrand; Nicholas M Snead; Holly M Micolochick Steuer; Kim Stever; Sunny Tang; Xiaohe Wang; Qiong Zhao; Michael J Sofia
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

8.  Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.

Authors:  Shuo Wu; Qiong Zhao; Pinghu Zhang; John Kulp; Lydia Hu; Nicky Hwang; Jiming Zhang; Timothy M Block; Xiaodong Xu; Yanming Du; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 9.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

10.  Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice.

Authors:  Zhihua Qi; Gaiyun Li; Hao Hu; Chunhui Yang; Xiaoming Zhang; Qibin Leng; Youhua Xie; Demin Yu; Xinxin Zhang; Yueqiu Gao; Ke Lan; Qiang Deng
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.